Cancer Stem Cell Plasticity Drives Therapeutic Resistance
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
The connection between epithelial-mesenchymal (E-M) plasticity and cancer stem cell (CSC) properties has been paradigm-shifting, linking tumor cell invasion and metastasis with therapeutic recurrence. However, despite their importance, the molecular pathways involved in generating invasive, metastatic, and therapy-resistant CSCs remain poorly understood. The enrichment of cells with a mesenchymal/CSC phenotype following therapy has been interpreted in two different ways. The original interpretation posited that therapy kills non-CSCs while sparing pre-existing CSCs. However, evidence is emerging that suggests non-CSCs can be induced into a transient, drug-tolerant, CSC-like state by chemotherapy. The ability to transition between distinct cell states may be as critical for the survival of tumor cells following therapy as it is for metastatic progression. Therefore, inhibition of the pathways that promote E-M and CSC plasticity may suppress tumor recurrence following chemotherapy. Here, we review the emerging appreciation for how plasticity confers therapeutic resistance and tumor recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 2×
“For example, breast CSCs were originally identified as having a CD24LoCD44Hi cell-surface marker profile [11].”
BackgroundInfluentialThe basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 1×
“Metastasis is most often thought to be initiated by epithelial cancer cells undergoing EMT, resulting in the dissolution of tight cell-cell interaction by downregulation of junctional/epithelial proteins (claudin, occludin, ZO1, E-cadherin, cytokeratins; [25,26]).”
BackgroundThe Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672 · cited 1×
“For example, the induction of EMT in immortalized and transformed human mammary epithelial cells (HMEC) by ectopic expression of Twist, Snail, or FoxC2 transcription factors induces EMT, concomitant with an increased ability to form tumorspheres in vitro and tumors in vivo [19,22,23].”
BackgroundMolecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Metastasis is most often thought to be initiated by epithelial cancer cells undergoing EMT, resulting in the dissolution of tight cell-cell interaction by downregulation of junctional/epithelial proteins (claudin, occludin, ZO1, E-cadherin, cytokeratins; [25,26]).”
BackgroundGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“CSCs avoid therapy-induced apoptotic signaling through more effective DNA damage responses evolved to protect genomic integrity [42,43].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“CSCs also express lower levels of pro-apoptotic proteins, such as caspase-8, and elevated levels of drug efflux pumps, such as MDR-1 and the p-glycoproteins [44], which transport chemotherapeutics out of the cell, rendering them ineffective [45,46].”
BackgroundGinestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012 · cited 1×
“Subsequently, elevated Aldehyde Dehydrogenase (ALDH) activity was also shown to correlate with CSC potential, although CD24LoCD44Hi and ALDH+ CSCs identify distinct CSC populations [15,16].”
BackgroundLiedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · cited 3×
“with poor survival and early recurrence [3–5,96].”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 1×
“Importantly, this drug-induced CSC-like phenotype was transient, as drug removal resulted in loss of CSC properties as cells differentiated into non-CSCs and regained drug sensitivity [51].”
BackgroundMetastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2622 · Cited by 2,649 · cited 1×
“Metastasis is the overwhelming cause of cancer mortality [1,2].”
BackgroundMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“CSCs also express lower levels of pro-apoptotic proteins, such as caspase-8, and elevated levels of drug efflux pumps, such as MDR-1 and the p-glycoproteins [44], which transport chemotherapeutics out of the cell, rendering them ineffective [45,46].”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 3×
“Differentiated, non-CSCs, which make up the bulk of a tumor, are more sensitive to conventional chemotherapies than CSCs are [7,20,40].”
BackgroundCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundBreast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412 · cited 1×
“Indeed, analysis of paired breast cancer core biopsies before and after chemotherapy demonstrates that a higher percentage of CD24LoCD44Hi CSCs capable of forming mammospheres exist in post-treatment biopsies [41].”
BackgroundKuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330 · cited 3×
“Following chemotherapy, the presence of residual disease at the time of surgery is associated with poor survival and early recurrence [3–5,96].”
BackgroundCancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287 · cited 4×
“Differentiated, non-CSCs, which make up the bulk of a tumor, are more sensitive to conventional chemotherapies than CSCs are [7,20,40].”
BackgroundInfluentialTumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234 · cited 2×
“Tumors are complex tissues composed of a hierarchical organization of tumor cell sub-populations as well as numerous tumor-associated stromal cell types [6].”
BackgroundEpithelial–mesenchymal plasticity in carcinoma metastasis
Tsai, J. H., & Yang, J. (2013) · Genes & Development · doi:10.1101/gad.225334.113 · Cited by 1,136 · cited 2×
“These include: (1) the induction of matrix metalloproteinases (MMPs) responsible for the degradation of the extracellular matrix (ECM) and tumor cell intravasation; (2) survival in the bloodstream (by creating multi-cell aggregates); and (3) extravasation (by enhanced membrane protrusions and blood vessel contacts [27…”
BackgroundLiu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.11.009 · Cited by 1,053 · cited 3×
“However, accumulating evidence supports the idea that non-CSCs can be induced into a drug-tolerant, CSC-like state by chemotherapy (Figure 1; [21,47–52]).”
BackgroundResultBaccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2576 · Cited by 1,047 · cited 1×
“Further evidence linking E-M plasticity and a CSC phenotype is provided by the observation that a sub-set of CTC responsible for initiating metastasis (termed the metastasis-initiating cells) express high levels of the CSC marker CD44 or ALDH1 [36–38].”
BackgroundTargeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893 · cited 1×
“Moreover, single-cell analysis recently identified distinct EMT and CSC gene expression patterns in early-stage breast cancer micro-metastases [39].”
BackgroundChaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 876 · cited 1×
“For example, the induction of EMT in immortalized and transformed human mammary epithelial cells (HMEC) by ectopic expression of Twist, Snail, or FoxC2 transcription factors induces EMT, concomitant with an increased ability to form tumorspheres in vitro and tumors in vivo [19,22,23].”
BackgroundInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757 · cited 1×
“In addition to TGFβ, additional cytokines and growth factors (IL4, IL6, OSM, IL10, TNFα, ILEI, IFNγ, and VEGF) have also been implicated in inducing EMT (and by extension, CSC properties; [57–62]).”
BackgroundThe therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundBadea, L., Herlea, V., Dima, S., Dumitraşcu, T., & Popescu, I. (2008) · PubMed · Cited by 618
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57099 · Cited by 616 · cited 2×
“Progeny emanating from CSCs depend not only on the genetic profile of the cell, but also, perhaps more importantly, on the TME surrounding the cell, which serves as the CSC niche [13,14,55].”
BackgroundBreast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611 · cited 1×
“Progeny emanating from CSCs depend not only on the genetic profile of the cell, but also, perhaps more importantly, on the TME surrounding the cell, which serves as the CSC niche [13,14,55].”
BackgroundGuarneri, V., Broglio, K., Kau, S.-W., Cristofanilli, M., Buzdar, A. U., Valero, V., Buchholz, T., Meric, F., Middleton, L., Hortobagyi, G. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6914 · Cited by 601 · cited 3×
“Following chemotherapy, the presence of residual disease at the time of surgery is associated with poor survival and early recurrence [3–5,96].”
BackgroundTGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590 · cited 1×
“Importantly, pharmacological suppression of TGFβ signaling with small molecule inhibitors suppressed the acquisition of CSC properties and prevented therapeutic resistance and tumor relapse in TNBC PDX mouse models [94].”
BackgroundEMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Suppression of cancer relapse and metastasis by inhibiting cancer stemness
Li, Y., Rogoff, H. A., Keates, S., Gao, Y., Murikipudi, S., Mikule, K., Leggett, D., Li, W., Pardee, A. B., & Li, C. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424171112 · Cited by 458 · cited 2×
“of cancers including pancreatic, head and neck and colorectal [97].”
BackgroundSachlos, E., Risueño, R. M., Laronde, S., Shapovalova, Z., Lee, J.-H., Russell, J., Malig, M., McNicol, J. D., Fiebig-Comyn, A., Graham, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.049 · Cited by 456
Queen, M. M., Ryan, R. E., Holzer, R. G., Keller-Peck, C. R., & Jorcyk, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1734 · Cited by 413 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
Backgroundvan den Hoogen, C., van der Horst, G., Cheung, H., Buijs, J. T., Lippitt, J. M., Guzmán-Ramírez, N., Hamdy, F. C., Eaton, C. L., Thalmann, G. N., Cecchini, M. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3806 · Cited by 398 · cited 1×
“Further evidence linking E-M plasticity and a CSC phenotype is provided by the observation that a sub-set of CTC responsible for initiating metastasis (termed the metastasis-initiating cells) express high levels of the CSC marker CD44 or ALDH1 [36–38].”
BackgroundLotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359 · cited 1×
“Recent comparison of matched patient-derived colorectal cancer samples before and after chemotherapy identified a significant increase in the secretion of IL-17A cytokine from Cancer Associated Fibroblasts (CAFs), which induced CSC properties, resulting in therapeutic resistance [93].”
BackgroundBiddle, A., Liang, X., Gammon, L., Fazil, B., Harper, L. J., Emich, H., Costea, D. E., & Mackenzie, I. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1059 · Cited by 356 · cited 2×
“However, accumulating evidence supports the idea that non-CSCs can be induced into a drug-tolerant, CSC-like state by chemotherapy (Figure 1; [21,47–52]).”
BackgroundLi, Q.-Q., Xu, J.-D., Wang, W.-J., Cao, X.-X., Chen, Q., Tang, F., Chen, Z.-Q., Liu, X.-P., & Xu, Z.-D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2372 · Cited by 338 · cited 2×
“However, accumulating evidence supports the idea that non-CSCs can be induced into a drug-tolerant, CSC-like state by chemotherapy (Figure 1; [21,47–52]).”
BackgroundRegulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2743 · Cited by 334
Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment
Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M. A., Ambartsumian, N., Sandelin, K., Rank, F., & Gromova, I. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400009-mcp200 · Cited by 305 · cited 1×
“Studies of breast tumor interstitial fluid have identified over 1000 distinct proteins present only in the TME [56].”
BackgroundBlick, T., Hugo, H., Widodo, E., Waltham, M., Pinto, C., Mani, S. A., Weinberg, R. A., Neve, R. M., Lenburg, M. E., & Thompson, E. W. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9175-z · Cited by 292 · cited 1×
“Our studies, along with the studies of others, have determined that transformed human mammary epithelial cells (HMEC) acquire CSC properties when they undergo EMT, in addition to acquiring an invasive, mesenchymal phenotype [9,17–21].”
ResultPisco, A. O., & Huang, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.146 · Cited by 283
Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
Wu, S., Liu, S., Liu, Z., Huang, J., Pu, X., Li, J., Yang, D., Deng, H., Yang, N., & Xu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123976 · Cited by 282 · cited 1×
“Likewise, the presence and abundance of circulating tumor cells (CTC) that express mesenchymal markers can be used to track a patient’s response to therapy [33–35].”
BackgroundMoitra, K., Lou, H., & Dean, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.14 · Cited by 279 · cited 1×
“CSCs also express lower levels of pro-apoptotic proteins, such as caspase-8, and elevated levels of drug efflux pumps, such as MDR-1 and the p-glycoproteins [44], which transport chemotherapeutics out of the cell, rendering them ineffective [45,46].”
BackgroundFOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
Hollier, B. G., Tinnirello, A. A., Werden, S. J., Evans, K. W., Taube, J. H., Sarkar, T. R., Sphyris, N., Shariati, M., Kumar, S. V., Battula, V. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2962 · Cited by 277 · cited 1×
“For example, the induction of EMT in immortalized and transformed human mammary epithelial cells (HMEC) by ectopic expression of Twist, Snail, or FoxC2 transcription factors induces EMT, concomitant with an increased ability to form tumorspheres in vitro and tumors in vivo [19,22,23].”
BackgroundGoldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M., Majumder, P. K., & Sengupta, S. (2015) · Nature Communications · doi:10.1038/ncomms7139 · Cited by 260 · cited 3×
“Importantly, the ability to re-sensitize these resistant cells was again temporally dependent, and only effective following chemotherapy, not as a pre- or co-treatment [47].”
BackgroundInfluentialMonoclonal Antibodies Against Lgr5 Identify Human Colorectal Cancer Stem Cells
Kemper, K., Prasetyanti, P. R., De Lau, W., Rodermond, H., Clevers, H., & Medema, J. P. (2012) · Stem Cells · doi:10.1002/stem.1233 · Cited by 257 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundCell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations
Rycaj, K., & Tang, D. G. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0798 · Cited by 256 · cited 2×
“Thus, rather than using specific markers, functional assays are necessary to truly define a CSC population, including the capacity for anchorage-independent growth (AIG) as tumorspheres and the ability to generate tumors following orthotopic implantation (typically at low cell numbers; [12]).”
BackgroundInfluentialSun, L., Yao, Y., Liu, B., Lin, Z., Lin, L., Yang, M., Zhang, W., Chen, W., Pan, C., Liu, Q., et al. (2012) · Oncogene · doi:10.1038/onc.2011.263 · Cited by 249
Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Satelli, A., Mitra, A., Brownlee, Z., Xia, X., Bellister, S., Overman, M. J., Kopetz, S., Ellis, L. M., Meng, Q. H., & Li, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0894 · Cited by 242 · cited 1×
“Likewise, the presence and abundance of circulating tumor cells (CTC) that express mesenchymal markers can be used to track a patient’s response to therapy [33–35].”
BackgroundAdorno-Cruz, V., Kibria, G., Liu, X., Doherty, M., Junk, D. J., Guan, D., Hubert, C., Venere, M., Mulkearns-Hubert, E., Sinyuk, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3225 · Cited by 240 · cited 2×
“The cancer stem cell (CSC) hypothesis places cells with self-renewal capacity and the ability to differentiate at the top of the tumor cell hierarchy [7–10].”
BackgroundResultSelf-citationHiraga, T., Ito, S., & Nakamura, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3801 · Cited by 226
Tripathi, C., Tewari, B. N., Kanchan, R. K., Baghel, K. S., Nautiyal, N., Shrivastava, R., Kaur, H., Bhatt, M. L. B., & Bhadauria, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2110 · Cited by 224 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundThe Enigmatic Cytokine Oncostatin M and Roles in Disease
Richards, C. D. (2013) · ISRN Inflammation · doi:10.1155/2013/512103 · Cited by 204 · cited 2×
“At the same time, cancer cells from more aggressive tumor types express markedly higher levels of OSM Receptor (OSMR) [64,77,78,92].”
BackgroundZhu, Q., Zhang, X., Zhang, L., Li, W., Wu, H., Yuan, X., Mao, F., Wang, M., Zhu, W., Qian, H., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.263 · Cited by 189
Waerner, T., Alacakaptan, M., Tamir, I., Oberauer, R., Gal, A., Brabletz, T., Schreiber, M., Jechlinger, M., & Beug, H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.020 · Cited by 186 · cited 1×
“In addition to TGFβ, additional cytokines and growth factors (IL4, IL6, OSM, IL10, TNFα, ILEI, IFNγ, and VEGF) have also been implicated in inducing EMT (and by extension, CSC properties; [57–62]).”
BackgroundOncostatin M Production and Regulation by Human Polymorphonuclear Neutrophils
Grenier, A., Dehoux, M., Boutten, A., Arce-Vicioso, M., Durand, G., Gougerot-Pocidalo, M.-A., & Chollet-Martin, S. (1999) · Blood · doi:10.1182/blood.v93.4.1413 · Cited by 177
Rakha, E. A., Abd El Rehim, D., Pinder, S. E., Lewis, S. A., & Ellis, I. O. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02156.x · Cited by 171 · cited 1×
“EMT in primary Triple Negative Breast Cancer (TNBC), as evidenced by loss of epithelial markers (E-cadherin) or gain of mesenchymal markers (Vimentin, N-Cadherin, Snail expression) typically at the tumor’s edge, correlates with poor clinical outcome in TNBC [28–32].”
BackgroundIonizing Radiation Induces Stemness in Cancer Cells
Ghisolfi, L., Keates, A. C., Hu, X., Lee, D.-K., & Li, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043628 · Cited by 165 · cited 1×
“Finally, carboplatin and ionizing radiation can also induce the emergence of CSC properties from non-CSCs, which is dependent on stem cell markers Sox2 and Oct3/4 [53,54].”
BackgroundRakha, E. A., Patel, A., Powe, D. G., Benhasouna, A., Green, A. R., Lambros, M. B. K., Reis-Filho, J. S., & Ellis, I. O. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181f01916 · Cited by 161 · cited 1×
“EMT in primary Triple Negative Breast Cancer (TNBC), as evidenced by loss of epithelial markers (E-cadherin) or gain of mesenchymal markers (Vimentin, N-Cadherin, Snail expression) typically at the tumor’s edge, correlates with poor clinical outcome in TNBC [28–32].”
BackgroundConcise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Pan, Q., Li, Q., Liu, S., Ning, N., Zhang, X., Xu, Y., Chang, A. E., & Wicha, M. S. (2015) · Stem Cells · doi:10.1002/stem.2039 · Cited by 151
Targeting apoptosis pathways in cancer stem cells
Signore, M., Ricci‐Vitiani, L., & Maria, R. D. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.013 · Cited by 143 · cited 1×
“CSCs avoid therapy-induced apoptotic signaling through more effective DNA damage responses evolved to protect genomic integrity [42,43].”
BackgroundPI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells
Kolev, V. N., Wright, Q. G., Vidal, C. M., Ring, J. E., Shapiro, I. M., Ricono, J. M., Weaver, D. T., Padval, M. V., Pachter, J. A., & Xu, Q. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1223 · Cited by 131 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundCharafe-Jauffret, E., Ginestier, C., Bertucci, F., Cabaud, O., Wicinski, J., Finetti, P., Josselin, E., Adelaide, J., Nguyen, T.-T., Monville, F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4704 · Cited by 128 · cited 1×
“Subsequently, elevated Aldehyde Dehydrogenase (ALDH) activity was also shown to correlate with CSC potential, although CD24LoCD44Hi and ALDH+ CSCs identify distinct CSC populations [15,16].”
BackgroundBreast Cancer Stem Cells: A Novel Therapeutic Target
Gangopadhyay, S., Nandy, A., Hor, P., & Mukhopadhyay, A. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.09.017 · Cited by 126 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundWest, N. R., Murray, J. I., & Watson, P. H. (2013) · Oncogene · doi:10.1038/onc.2013.105 · Cited by 124 · cited 1×
“Moreover, exposure of cancer cells or pre-malignant HMEC to OSM is sufficient to induce EMT, acquisition of CSC properties, and an invasive and transformed phenotype [61,63].”
BackgroundGonzález-Moreno, Ó., Lecanda, J., Green, J. E., Segura, V., Catena, R., Serrano, D., & Calvo, A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.11.020 · Cited by 114
Royuela, M., Ricote, M., Parsons, M. S., García‐Tuñón, I., Paniagua, R., & De Miguel, M. P. (2004) · The Journal of Pathology · doi:10.1002/path.1476 · Cited by 110 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundInduction of cancer cell stemness by chemotherapy
Hu, X., Ghisolfi, L., Keates, A. C., Zhang, J., Xiang, S., Lee, D.-K., & Li, C. J. (2012) · Cell Cycle · doi:10.4161/cc.21021 · Cited by 110 · cited 1×
“Finally, carboplatin and ionizing radiation can also induce the emergence of CSC properties from non-CSCs, which is dependent on stem cell markers Sox2 and Oct3/4 [53,54].”
BackgroundLiu, T., Zhang, X., Shang, M., Zhang, Y., Xia, B., Niu, M., Liu, Y., & Pang, D. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23240 · Cited by 97 · cited 1×
“EMT in primary Triple Negative Breast Cancer (TNBC), as evidenced by loss of epithelial markers (E-cadherin) or gain of mesenchymal markers (Vimentin, N-Cadherin, Snail expression) typically at the tumor’s edge, correlates with poor clinical outcome in TNBC [28–32].”
BackgroundLiu, X. (2008) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20315 · Cited by 88 · cited 1×
“In addition to TGFβ, additional cytokines and growth factors (IL4, IL6, OSM, IL10, TNFα, ILEI, IFNγ, and VEGF) have also been implicated in inducing EMT (and by extension, CSC properties; [57–62]).”
BackgroundCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapy
Miller, E., Lee, H. J., Lulla, A. R., Hernandez, L., Gokare, P. R., & Lim, B. (2014) · F1000Research · doi:10.12688/f1000research.4340.1 · Cited by 87 · cited 1×
“Novel therapeutic strategies have been proposed which combine conventional cancer therapies with specific inhibitors targeting CSCs [97–106].”
BackgroundWest, N. R., Murphy, L. C., & Watson, P. H. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0326 · Cited by 78
Oncostatin M Promotes Mammary Tumor Metastasis to Bone and Osteolytic Bone Degradation
Bolin, C., Tawara, K., Sutherland, C., Redshaw, J. D., Aranda, P., Moselhy, J., Anderson, R. L., & Jorcyk, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912458284 · Cited by 77 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundVlaicu, P., Mertins, P., Mayr, T., Widschwendter, P., Ataseven, B., Högel, B., Eiermann, W., Knyazev, P., & Ullrich, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-197 · Cited by 76
Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma
Caffarel, M. M., & Coleman, N. (2013) · The Journal of Pathology · doi:10.1002/path.4305 · Cited by 75 · cited 2×
“At the same time, cancer cells from more aggressive tumor types express markedly higher levels of OSM Receptor (OSMR) [64,77,78,92].”
BackgroundAtkinson, R. L., Yang, W. T., Rosen, D. G., Landis, M. D., Wong, H. H., Lewis, M. T., Creighton, C. J., Sexton, K. R., Hilsenbeck, S. G., Şahin, A. A., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3471 · Cited by 74 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundOncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells
Repovic, P., Fears, C. Y., Gladson, C. L., & Benveniste, E. N. (2003) · Oncogene · doi:10.1038/sj.onc.1206922 · Cited by 74
Jorcyk, C. L., Holzer, R. G., & RYAN, R. (2006) · Cytokine · doi:10.1016/j.cyto.2006.03.004 · Cited by 67 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundOncostatin M Production by Blood and Alveolar Neutrophils during Acute Lung Injury
Grenier, A., Combaux, D., Chastre, J. E., Gougerot-Pocidalo, M. A., Gibert, C., Dehoux, M., & Chollet‐Martin, S. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780220 · Cited by 66 · cited 1×
“OSM in the TME may originate from immune cells, adipose tissue, as well as cancer cells [84–89].”
BackgroundLiu, W., Chen, M.-T., Wang, M., Lee, Y., Chiou, G., Chien, C., Huang, P., Chen, Y., Huang, M., Chiou, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2737 · Cited by 65 · cited 2×
“and stemness-related factors, respectively [95,96].”
BackgroundTechasen, A., Loilome, W., Namwat, N., Dokduang, H., Jongthawin, J., & Yongvanit, P. (2012) · PubMed · Cited by 63
Smith, D. A., Kiba, A., Zong, Y., & Witte, O. N. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0238 · Cited by 60 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundRyan, R. E., Martin, B. T., Mellor, L. F., Jacob, R. B., Tawara, K., McDougal, O. M., Oxford, J. T., & Jorcyk, C. L. (2015) · Cytokine · doi:10.1016/j.cyto.2014.11.007 · Cited by 58 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundGarcía‐Tuñón, I., Ricote, M., Ruiz, A., Fraile, B., Paniagua, R., & Royuela, M. (2008) · Cancer Investigation · doi:10.1080/07357900701638491 · Cited by 56 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundWong, S. C., Botelho, F. M., Rodrigues, R., & Richards, C. D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.81 · Cited by 55 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundNg, G., Winder, D. M., Muralidhar, B., Gooding, E. L., Roberts, I., Pett, M. R., Mukherjee, G., Huang, J., & Coleman, N. (2007) · The Journal of Pathology · doi:10.1002/path.2184 · Cited by 52 · cited 2×
“At the same time, cancer cells from more aggressive tumor types express markedly higher levels of OSM Receptor (OSMR) [64,77,78,92].”
BackgroundSerum Cytokine Profile in Patients With Pancreatic Cancer
Torres, C., Perales, S., Alejandre, M. J., Iglesias, J., Palomino‐Morales, R., Martín, M., Caba, O., Prados, J. C., Aránega, A., Delgado, J. R., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000155 · Cited by 51 · cited 1×
“Moreover, DNA damaging chemotherapy induces additional OSM secretion from macrophages, potentially exacerbating the aggressive properties associated with mesenchymal and CSC properties following treatment with genotoxic therapies [83,90,91].”
BackgroundOncostatin M Confers Neuroprotection against Ischemic Stroke
Guo, S., Li, Z., Gong, J., Xiang, M., Zhang, P., Zhao, G., Li, M., Zheng, A., Zhu, X., Lei, H., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1800-15.2015 · Cited by 49 · cited 1×
“OSM in the TME may originate from immune cells, adipose tissue, as well as cancer cells [84–89].”
BackgroundWinder, D. M., Chattopadhyay, A., Muralidhar, B., Bauer, J., English, W., Zhang, X., Karagavriilidou, K., Roberts, I., Pett, M. R., Murphy, G., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2968 · Cited by 47 · cited 2×
“At the same time, cancer cells from more aggressive tumor types express markedly higher levels of OSM Receptor (OSMR) [64,77,78,92].”
BackgroundSeeing is Believing: Are Cancer Stem Cells the Loch Ness Monster of Tumor Biology?
Lathia, J. D., Venere, M., Rao, M. S., & Rich, J. N. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9194-6 · Cited by 47
Yue, Y. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.647 · Cited by 46
Holzer, R. G., Ryan, R. E., Tommack, M., Schlekeway, E., & Jorcyk, C. L. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000024760.02667.db · Cited by 44 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundJunk, D. J., Cipriano, R., Bryson, B. L., Gilmore, H. L., & Jackson, M. W. (2013) · Neoplasia · doi:10.1593/neo.131114 · Cited by 42
Self-citationNovel function of Oncostatin M as a potent tumour‐promoting agent in lung
Lauber, S., Wong, S. C., Cutz, J., Tanaka, M., Barra, N. G., Lhoták, Š., Ashkar, A. A., & Richards, C. D. (2014) · International Journal of Cancer · doi:10.1002/ijc.29055 · Cited by 42 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundLevano, K. S., Jung, E. H., & Kenny, P. A. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.102 · Cited by 39 · cited 1×
“Expression of OSMR correlates with the increased expression of the CSC marker CD44 and mesenchymal markers, most frequently at the invasive edge of the tumor near the OSM-secreting macrophages [84,89].”
BackgroundOncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis
Zhu, M., Che, Q., Liao, Y. J., Wang, H., WANG, J., Chen, Z., Wang, F., DAI, C., & Wan, X. (2015) · Oncology Reports · doi:10.3892/or.2015.3951 · Cited by 38 · cited 1×
“Elevated levels of OSM in the TME are associated with highly aggressive metastatic cancers and an increased risk of tumor recurrence (chemotherapy resistance) in a variety of tumor types [61,63–83].”
BackgroundKan, C. E., Cipriano, R., & Jackson, M. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3860 · Cited by 37 · cited 1×
“Moreover, exposure of cancer cells or pre-malignant HMEC to OSM is sufficient to induce EMT, acquisition of CSC properties, and an invasive and transformed phenotype [61,63].”
BackgroundSelf-citationMarkiewicz, A., Wełnicka-Jaśkiewicz, M., Seroczyńska, B., Skokowski, J., Majewska, H., Szade, J., & Zaczek, A. J. (2014) · Europe PMC (PubMed Central) · Cited by 30
Cisplatin‐stimulated murine bone marrow‐derived macrophages secrete oncostatin M
Sodhi, A., Shishodia, S., & Shrivastava, A. (1997) · Immunology and Cell Biology · doi:10.1038/icb.1997.76 · Cited by 23 · cited 1×
“Moreover, DNA damaging chemotherapy induces additional OSM secretion from macrophages, potentially exacerbating the aggressive properties associated with mesenchymal and CSC properties following treatment with genotoxic therapies [83,90,91].”
BackgroundSingh, R. A., & Sodhi, A. (1998) · Immunology Letters · doi:10.1016/s0165-2478(98)00040-6 · Cited by 20
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy
Chen, W., Dong, J., Haiech, J., Kilhoffer, M.-C., & Zeniou, M. (2016) · Stem Cells International · doi:10.1155/2016/1740936 · Cited by 402
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Metadata
- Authors
- Doherty, M., Smigiel, J., Junk, D., & Jackson, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2016-01-05
- Volume
- 8
- Issue
- 1
- Pages
- 8
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2226316051
- Cited by
- 160
- References
- 104
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.